4.8 Article

Development of Surface Chemical Strategies for Synthesizing Redox-Responsive Diatomite Nanoparticles as a Green Platform for On-Demand Intracellular Release of an Antisense Peptide Nucleic Acid Anticancer Agent

Journal

SMALL
Volume 18, Issue 41, Pages -

Publisher

WILEY-V C H VERLAG GMBH
DOI: 10.1002/smll.202204732

Keywords

diatomite nanoparticles; gene therapy; peptide nucleic acids; redox-responsive; surface chemistry

Funding

  1. Programma Operativo Nazionale-Attraction and Internetional Mobility (PON-AIM) RTDA_L1 [AIM 1873131-2]
  2. Sigrid Juselius Foundation
  3. Academy of Finland [331151]
  4. UMCG Research Funds

Ask authors/readers for more resources

Redox-responsive silica drug delivery systems were synthesized using eco-friendly diatomite source to achieve on-demand release of peptide nucleic acid (PNA) in tumor reducing microenvironment, inhibiting immune check-point PD-1/PD-L1 in cancer cells. The systems showed safety and advantages in controlling and enhancing PNA release, paving the way for targeted immunotherapy.
Redox-responsive silica drug delivery systems are synthesized by aeco-friendly diatomite source to achieve on-demand release of peptide nucleic acid (PNA) in tumor reducing microenvironment, aiming to inhibit the immune check-point programmed cell death 1 receptor/programmed cell death receptor ligand 1 (PD-1/PD-L1) in cancer cells. The nanoparticles (NPs) are coated with polyethylene glycol chains as gatekeepers to improve their physicochemical properties and control drug release through the cleavable disulfide bonds (S-S) in a reductive environment. This study describes different chemical conditions to achieve the highest NPs' surface functionalization yield, exploring both multistep and one-pot chemical functionalization strategies. The best formulation is used for covalent PNA conjugation via the S-S bond reaching a loading degree of 306 +/- 25 mu g (PNA) mg(DNPs)(-1). These systems are used for in vitro studies to evaluate the kinetic release, biocompatibility, cellular uptake, and activity on different cancer cells expressing high levels of PD-L1. The obtained results prove the safety of the NPs up to 200 mu g mL(-1) and their advantage for controlling and enhancing the PNA intracellular release as well as antitumor activity. Moreover, the downregulation of PD-L1 observed only with MDA-MB-231 cancer cells paves the way for targeted immunotherapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available